

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.



Gynecomastia ~~Treatment Surgery~~ (for Louisiana Only)

Policy Number: CS051LA.±J

Effective Date: TBD

[➔ Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Definitions	3
Applicable Codes	3
Description of Services	4
Clinical Evidence	4
U.S. Food and Drug Administration	5
References	5
Policy History/Revision Information	6
Instructions for Use	6
Archived Policy Versions	Error! Bookmark not defined.

Application

This Medical Policy only applies to the state of Louisiana.

Coverage Rationale

Indications for Coverage

~~Most UnitedHealthcare plans have a specific exclusion for treatment of Benign Gynecomastia. Refer to the Coverage Limitations and Exclusions section.~~

~~Criteria for a Coverage Determination that Surgery is Reconstructive and Medically Necessary~~

~~A m~~Mastectomy ~~or suction lipectomy~~ for treatment of Benign Gynecomastia for a male member under age 18 is considered reconstructive and medically necessary when all the following criteria are met:

- Gynecomastia or breast enlargement with moderate to severe chest pain that is causing a [Functional or Physical Impairment](#). The inability to participate in athletic events, sports or social activities is not considered to be a functional or physical or physiological impairment.
- Persistent gynecomastia after cessation of prescribed medications and appropriate screening(s) of non-prescription and/or recreational drugs or substances that have a known side effect of gynecomastia (examples include, but are not limited to the following: testosterone, marijuana, asthma drugs, phenothiazines, anabolic steroids, cimetidine and calcium channel blockers).

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

- The breast enlargement must be present for at least 2 years and appropriate evaluation of medical causes with supporting laboratory testing has been normal. If so, lab tests which might include, but are not limited to the following must be performed:
 - Hormone testing (e.g., beta-human chorionic gonadotropin, estradiol, follicle-stimulating hormone, luteinizing hormone, prolactin, testosterone)
 - Liver enzymes
 - Serum creatinine
 - Thyroid function studies

Mastectomy ~~or suction lipectomy~~ for treatment of Benign Gynecomastia for a male member age 18 and over is considered reconstructive and medically necessary when all the following criteria are met:

- Discontinuation of medications, nutritional supplements, and non-prescription medications or substances (examples include, but are not limited to the following: testosterone, marijuana, asthma drugs, phenothiazines, anabolic steroids, cimetidine and calcium channel blockers) that have a known side effect of gynecomastia or breast enlargement and the breast size did not regress after discontinuation of use as appropriate.
- Glandular breast tissue is the primary cause of gynecomastia as opposed to fatty deposits (pseudo gynecomastia) and is documented on physical exam and/or mammography.
- Gynecomastia or breast enlargement with moderate to severe chest pain that is causing a [Functional or Physical Impairment](#). The inability to participate in athletic events, sports or social activities is not considered to be a functional or physical or physiological impairment.
- Appropriate evaluation of medical causes with supporting laboratory testing has been normal. If so, lab tests which might include, but are not limited to the following must be performed:
 - Hormone testing (e.g., beta-human chorionic gonadotropin, follicle-stimulating hormone, estradiol, luteinizing hormone, prolactin, testosterone)
 - Liver enzymes
 - Serum creatinine
 - Thyroid function studies

Note: Regardless of age, if a tumor or neoplasm is suspected, a breast ultrasound and/or mammogram may be performed. As indicated, a breast biopsy may also be performed.

Coverage Limitations and Exclusions

~~UnitedHealthcare excludes Cosmetic Procedures from coverage including but not limited to the following:~~

- ~~• Procedures that correct an anatomical Congenital Anomaly without improving or restoring physiologic function are considered Cosmetic Procedures. The fact that a Covered Person may suffer psychological consequences or socially avoidant behavior as a result of an Injury, Sickness or Congenital Anomaly does not classify surgery (or other procedures done to relieve such consequences or behavior) as a reconstructive procedure.~~
- ~~• Treatment of Benign Gynecomastia when specifically excluded in the member specific benefit plan document.~~

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Definitions

Check the definitions within the federal, state, and contractual requirements that supersede the definitions below.~~Check the definitions within the member benefit plan document that supersede the definitions below.~~

Benign Gynecomastia: The development of abnormally large breasts in males. It is related to the excess growth of breast tissue (glandular), rather than excess fat tissue. (In most cases, breast enlargement and/or Benign Gynecomastia spontaneously resolves by age 18 making treatment unnecessary. Gynecomastia during puberty is not uncommon and in 90% of cases regresses within 3 years of onset.)

Congenital Anomaly: A physical developmental defect that is present at the time of birth, and that is identified within the first twelve months of birth.

Cosmetic Procedures: Procedures or services that change or improve appearance without significantly improving physiological function.

Functional or Physical Impairment: A Functional or Physical or physiological Impairment causes deviation from the normal function of a tissue or organ. This results in a significantly limited, impaired, or delayed capacity to move, coordinate actions, or perform physical activities and is exhibited by difficulties in one or more of the following areas: physical and motor tasks; independent movement; performing basic life functions.

Reconstructive Procedures: Reconstructive Procedures when the primary purpose of the procedure is either of the following:

- Treatment of a medical condition
- Improvement or restoration of physiologic function

Reconstructive Procedures include surgery or other procedures which are related to an Injury, Sickness or Congenital Anomaly. The primary result of the procedure is not a changed or improved physical appearance.

Procedures that correct an anatomical Congenital Anomaly without improving or restoring physiologic function are considered Cosmetic Procedures. The fact that you may suffer psychological consequences or socially avoidant behavior as a result of an Injury, Sickness or Congenital Anomaly does not classify surgery (or other procedures done to relieve such consequences or behavior) as a ~~R~~reconstructive ~~P~~procedure.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Note: Coding for suction lipectomy is addressed in the ~~Coverage Determination Guideline~~ **Medical Policy** titled Panniculectomy and Body Contouring Procedures (for Louisiana Only).

CPT Code	Description
19300	Mastectomy for gynecomastia

CPT® is a registered trademark of the American Medical Association

Description of Services

Gynecomastia is a benign proliferation of glandular breast tissue in men. Physiologic gynecomastia is common in newborns, adolescents, and older men. Treatment is directed at minimizing emotional distress and physical discomfort. Nonphysiologic gynecomastia may be caused by chronic conditions including but not limited to cirrhosis, hypogonadism, and renal insufficiency; use of medications, supplements, or illicit drugs; and, rarely, tumors. Discontinuing use of contributing medications and treating underlying disease is the standard of practice. Medications, such as estrogen receptor modulators, and surgery have a role in treating gynecomastia in select patients. Mastectomy refers to the surgical removal of glandular breast tissue through an open incision or more recently, through minimally endoscopic techniques. Cases that are considered severe may require larger incisions.

Clinical Evidence

Zavlin D et al. (2017) performed a retrospective analysis from the databases of the American College of Surgeons National Surgical Quality Improvement Program for adults and pediatrics to produce two cohorts that underwent surgical repair of gynecomastia. The goal of the study was to assess patient demographics, surgical outcomes and complications. A total of 1787 individuals were identified, 204 pediatric and 1583 adult males. Mean ages were 15.8 and 39.6 respectively. The results demonstrated low surgical (3.9 and 1.9%) and medical (0.0 and 0.3%) complications within the standardized 30-day postoperative period. Children and adolescents, however, required double mean operative times compared to adults (111.3 vs 56.7 min). The authors concluded that operative gynecomastia treatment remains a safe modality across all age groups.

Hayes (2010) published a health technology assessment for Mastectomy for gynecomastia. This assessment was based on 7 retrospective studies that included more than 50 individuals and 1 small prospective case series with 36 individuals. In the largest retrospective study by Petty et al. (2010) the efficacy and safety of 4 surgical procedures were compared involving 227 individuals. The participants were divided into 4 groups. Each group underwent a different surgical procedure. Mean follow-up was 6 months. Despite positive findings, weaknesses of this study include its retrospective design, loss to follow-up, and lack of blind assessment of the results. Evaluation of the other retrospective studies and small prospective case series resulted in similar conclusions. However, the evidence suggests that surgery for gynecomastia is an appropriate option for carefully selected patients with symptomatic persistent disease who have not responded to medical therapy, when surgery is performed by a surgeon with experience in the selected technique, and when tissue is submitted for histopathological examination.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

In a prospective randomized clinical trial Saariniemi et al. (2007) investigated the effectiveness of reduction mammoplasty for treatment of symptomatic breast hypertrophy. 82 individuals participated in the study. 40 individuals were part of the operative group, and 42 individuals to the nonoperative group. Both groups were examined at 0 and 6 months using short form-36 quality of life questionnaire, 15D quality of life questionnaire, the Finnish Pain Questionnaire and analysis of covariance was applied for instrumental data comparison. 29 participants in the operative group and 35 participants in the nonoperative group completed the study. The mean age was 46 years. Although the study resulted in the recommendation that reduction mammoplasty results in significant improvement of quality of life and decrease in pain and breast-associated symptoms it also noted that future studies should be focused on patient on participant selection and justification of the treatment by comparing with other approved treatments.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Surgeries for the treatment of gynecomastia are procedures and therefore not regulated by the FDA. See the following website for additional information:
<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed January 25, 2022).

References

Ali O, Donohue PA. Gynecomastia. In: Kliegman RM, Stanton BF, Geme JW, Schor NF, Behrman RE, eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 579.

Ansstas, G, Ansstas, M, Griffing, G, Gynecomastia. Medscape. Updated March 21, 2017.

Dickson, Gretchen, Gynecomastia, University of Kansas School of Medicine, April 1, 2012, Volume 85, Number 7.

Gynecomastia and hormones. Sansone A et al. Endocrine. 2017.

Gynecomastia in Infants, Children, and Adolescents. Leung AKC et al. Recent Pat Endocr Metab Immune Drug Discov. 2017.

Hayes, Health Technology Assessment, Mastectomy for Gynecomastia, Jul 12, 2012. Archived Aug 5, 2013.

Mayo Clinic: Diseases and Conditions. Gynecomastia (enlarged breasts in men). January 22, 2014.

Narula HS, Carlson HE. Gynecomastia. Endocrinol Metab Clin North Am. 2007/36:497-519. NIH Medline Plus. Updated December 19, 2014.

Saariniemi KM, Keranen UH, Salminen-Peltola PK et al. Reduction mammoplasty is effective treatment according to two quality of life instruments. A prospective randomised clinical trial. Journal of Plastic, Reconstructive & Aesthetic Surgery, 2008-12-01, Volume 61, Issue 12.

Zavlin D, Jubbal KT, Friedman JD, et al. Complications and Outcomes After Gynecomastia Surgery: Analysis of 204 Pediatric and 1583 Adult Cases from a National Multi-center Database. Aesthetic Plast Surg. 2017 Aug;41(4):761-767.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Policy History/Revision Information

Date	Summary of Changes
Xx/01/202Y	<p><u>Title Change</u></p> <ul style="list-style-type: none"> Previously titled <u>Gynecomastia Treatment (for Louisiana Only)</u> <p><u>Template Update</u></p> <ul style="list-style-type: none"> Changed policy type classification from "Coverage Determination Guideline" to "Medical Policy" <p><u>Coverage Rationale</u></p> <ul style="list-style-type: none"> Replaced language indicating: <ul style="list-style-type: none"> "Mastectomy or suction lipectomy for treatment of Benign Gynecomastia for a male member under age 18 [is reconstructive and medically necessary] when all of the [listed] criteria are met" with "a mastectomy for treatment of Benign Gynecomastia for a male member under age 18 is <i>considered</i> reconstructive and medically necessary when all the [listed] criteria are met" "Mastectomy or suction lipectomy for treatment of Benign Gynecomastia for a male member age 18 and up [is reconstructive and medically necessary] when all of the [listed] criteria are met" with "Mastectomy for treatment of Benign Gynecomastia for a male member age 18 and over is <i>considered</i> reconstructive and medically necessary when all the [listed] criteria are met" Removed language pertaining to coverage limitations and exclusions <p><u>Supporting Information</u></p> <ul style="list-style-type: none"> Added <u>Description of Services, Clinical Evidence, and FDA sections</u> Updated <u>References</u> section to reflect the most current information <p><u>Archived previous policy version CS051LA.I</u></p>

Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.